Clinical trials
Genetic Diseases, Inborn trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Terminated | 6 |
| Recruiting | 5 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vertex Pharmaceuticals Incorporated | 4 |
| BioMarin Pharmaceutical | 2 |
| Eloxx Pharmaceuticals, Inc. | 2 |
| Novartis Pharmaceuticals | 2 |
| PTC Therapeutics | 2 |
| Pfizer | 2 |
| Quince Therapeutics S.p.A. | 2 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Avidity Biosciences, Inc. | 1 |
| CSL Behring | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Genetic Diseases, Inborn | 29 |
| Nervous System Diseases | 9 |
| Musculoskeletal Diseases | 7 |
| Muscular Diseases | 6 |
| Muscular Disorders, Atrophic | 6 |
| Muscular Dystrophies | 6 |
| Neuromuscular Diseases | 6 |
| Hematologic Diseases | 4 |
| Muscular Dystrophy, Duchenne | 4 |
| Blood Coagulation Disorders | 3 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.